{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:42:41Z","timestamp":1792543361262,"version":"4.5.0"},"reference-count":109,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,7,17]],"date-time":"2018-07-17T00:00:00Z","timestamp":1531785600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2018.00790","type":"journal-article","created":{"date-parts":[[2018,7,17]],"date-time":"2018-07-17T01:09:00Z","timestamp":1531789740000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1006,"title":["Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization"],"prefix":"10.3389","volume":"9","author":[{"given":"Susan","family":"Hua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria B. C.","family":"de Matos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josbert M.","family":"Metselaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert","family":"Storm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,7,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3389\/fphar.2018.00228","article-title":"Risk Assessment and Risk Minimization in Nanomedicine: A Need for Predictive, Alternative, and 3Rs Strategies","volume":"9","author":"Accomasso","year":"2018","journal-title":"Frontiers in Pharmacology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1126\/science.1095833","article-title":"Drug delivery systems: entering the mainstream","volume":"303","author":"Allen","year":"2004","journal-title":"Science"},{"key":"B3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: from concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Del. Rev"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.2217\/nnm.15.156","article-title":"Quo vadis nanomedicine?","volume":"10","author":"Barz","year":"2015","journal-title":"Nanomedicine"},{"key":"B5","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.nano.2005.10.009","article-title":"Will the nanomedicine \u201cpatent land grab\u201d thwart commercialization?","volume":"1","author":"Bawa","year":"2005","journal-title":"Nanomedicine"},{"key":"B6","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2217\/17435889.2.3.351","article-title":"Patents and nanomedicine","volume":"2","author":"Bawa","year":"2007","journal-title":"Nanomedicine"},{"key":"B7","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.nano.2005.03.009","article-title":"Protecting new ideas and inventions in nanomedicine with patents","volume":"1","author":"Bawa","year":"2005","journal-title":"Nanomedicine"},{"key":"B8","first-page":"10","article-title":"Nanopharmaceuticals - patenting issues and FDA regulatory challenges","volume":"5","author":"Bawa","year":"2008","journal-title":"Am. Bar Assoc. SciTech Lawyer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.addr.2013.11.009","article-title":"Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology","volume":"66","author":"Bertrand","year":"2014","journal-title":"Adv. Drug Deliv. Rev"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1002\/nbm.3369","article-title":"Three-dimensional dynamic contrast-enhanced MRI for the accurate, extensive quantification of microvascular permeability in atherosclerotic plaques","volume":"28","author":"Calcagno","year":"2015","journal-title":"NMR Biomed"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e1416","DOI":"10.1002\/wnan.1416","article-title":"Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials","volume":"9","author":"Caster","year":"2017","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.jconrel.2010.09.011","article-title":"Liposomal pravastatin inhibits tumor growth by targeting cancer-related inflammation","volume":"148","author":"Coimbra","year":"2010","journal-title":"J. Control Release"},{"key":"B13","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jconrel.2011.12.014","article-title":"Drug targeting systems for inflammatory disease: one for all, all for one","volume":"161","author":"Crielaard","year":"2012","journal-title":"J. Control Release"},{"key":"B14","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jconrel.2016.11.015","article-title":"To exploit the tumor microenvironment: since the EPR effect fails in the clinic, what is the future of nanomedicine?","volume":"244","author":"Danhier","year":"2016","journal-title":"J. Control. Release."},{"key":"B15","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jconrel.2010.08.027","article-title":"To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery","volume":"148","author":"Danhier","year":"2010","journal-title":"J. Control Release"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1096\/fj.10-0503","article-title":"From \u201cbanghasomes\u201d to liposomes: a memoir of Alec Bangham, 1921-2010","volume":"24","author":"Deamer","year":"2010","journal-title":"FASEB J"},{"key":"B17","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1208\/s12248-012-9377-y","article-title":"Engineered nanoparticulate drug delivery systems: the next frontier for oral administration?","volume":"14","author":"Diab","year":"2012","journal-title":"AAPS J"},{"key":"B18","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jconrel.2013.05.025","article-title":"Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines","volume":"172","author":"Dobrovolskaia","year":"2013","journal-title":"J Control Release"},{"key":"B19","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3109\/17435390.2014.991431","article-title":"Towards an alternative testing strategy for nanomaterials used in nanomedicine: lessons from NanoTEST","author":"Dusinska","year":"2015","journal-title":"Nanotoxicology"},{"key":"B20","volume-title":"Guidance for Industry - INDs for Phase 2 and Phase 3 Studies: Chemistry, Manufacturing, and Control (CMC) Information","year":"2003"},{"key":"B21","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.cbpa.2005.06.001","article-title":"Nanovector therapeutics","volume":"9","author":"Ferrari","year":"2005","journal-title":"Curr. Opin. Chem. Biol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.healthpol.2011.06.001","article-title":"A new prize system for drug innovation","volume":"102","author":"Gandjour","year":"2011","journal-title":"Health Policy"},{"key":"B23","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2217\/17435889.2.2.143","article-title":"Regulatory issues surrounding nanomedicines: setting the scene for the next generation of nanopharmaceuticals","volume":"2","author":"Gaspar","year":"2007","journal-title":"Nanomedicine"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.addr.2009.06.003","article-title":"Polymeric carriers: preclinical safety and the regulatory implications for design and development of polymer therapeutics","volume":"61","author":"Gaspar","year":"2009","journal-title":"Adv. Drug Deliv. Rev"},{"key":"B25","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.ijpharm.2013.04.061","article-title":"Connecting drug delivery reality to smart materials design","volume":"454","author":"Grainger","year":"2013","journal-title":"Int. J. Pharm"},{"key":"B26","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/0014-5793(71)80109-6","article-title":"Enzyme entrapment in liposomes","volume":"14","author":"Gregoriadis","year":"1971","journal-title":"FEBS Lett"},{"key":"B27","doi-asserted-by":"publisher","first-page":"58P","DOI":"10.1042\/bj1240058P","article-title":"Liposomes as carriers of enzymes or drugs: a new approach to the treatment of storage diseases","volume":"124","author":"Gregoriadis","year":"1971","journal-title":"Biochem. J"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.2147\/IJN.S55359","article-title":"Nanotherapeutics in the EU: an overview on current state and future directions","volume":"9","author":"Hafner","year":"2014","journal-title":"Int. J. Nanomedicine"},{"key":"B29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.addr.2016.04.025","article-title":"Challenges and strategies in anti-cancer nanomedicine development: an industry perspective","volume":"108","author":"Hare","year":"2017","journal-title":"Adv. Drug. Deliv. Rev"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/S0002-9440(10)65006-7","article-title":"Openings between defective endothelial cells explain tumor vessel leakiness","volume":"156","author":"Hashizume","year":"2000","journal-title":"Am. J. Pathol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"4607","DOI":"10.1073\/pnas.95.8.4607","article-title":"Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment","volume":"95","author":"Hobbs","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"B32","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3389\/fphar.2013.00127","article-title":"Targeting sites of inflammation: intercellular adhesion molecule-1 as a target for novel inflammatory therapies","volume":"4","author":"Hua","year":"2013","journal-title":"Front. Pharmacol"},{"key":"B33","doi-asserted-by":"crossref","first-page":"E199","DOI":"10.36076\/ppj.2013\/16\/E199","article-title":"Targeted nanoparticles that mimic immune cells in pain control inducing analgesic and anti-inflammatory actions: a potential novel treatment of acute and chronic pain condition","volume":"16","author":"Hua","year":"2013","journal-title":"Pain Physician"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.nano.2015.02.018","article-title":"Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: Selective targeting to diseased versus healthy tissue","volume":"11","author":"Hua","year":"2015","journal-title":"Nanomedicine"},{"key":"B35","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3389\/fphar.2013.00143","article-title":"The use of lipid-based nanocarriers for targeted pain therapies","volume":"4","author":"Hua","year":"2013","journal-title":"Front. Pharmacol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1517\/17425247.2012.702751","article-title":"Lipid-based carriers: manufacturing and applications for pulmonary route","volume":"9","author":"Jaafar-Maalej","year":"2012","journal-title":"Expert Opin. Drug Deliv"},{"key":"B37","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.nano.2015.12.377","article-title":"Comparison of complement activation-related pseudoallergy in miniature and domestic pigs: foundation of a validatable immune toxicity model","volume":"12","author":"Jackman","year":"2016","journal-title":"Nanomedicine"},{"key":"B38","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.addr.2015.10.023","article-title":"Dual delivery of biological therapeutics for multimodal and synergistic cancer therapies","volume":"98","author":"Jang","year":"2016","journal-title":"Adv. Drug Deliv. Rev"},{"key":"B39","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.addr.2016.06.011","article-title":"Recent progress in development of siRNA delivery vehicles for cancer therapy","volume":"104","author":"Kim","year":"2016","journal-title":"Adv. Drug. Deliv. Rev"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1060028018764923","DOI":"10.1177\/1060028018764923","article-title":"Daunorubicin and cytarabine liposome in newly diagnosed therapy-related Acute Myeloid Leukemia (AML) or AML with myelodysplasia-related changes","volume":"1","author":"Kim","year":"2018","journal-title":"Ann. Pharmacother"},{"key":"B41","doi-asserted-by":"publisher","first-page":"6732","DOI":"10.1158\/0008-5472.CAN-05-4199","article-title":"Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models","volume":"66","author":"Kirpotin","year":"2006","journal-title":"Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1021\/bi962148u","article-title":"Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro","volume":"36","author":"Kirpotin","year":"1997","journal-title":"Biochemistry"},{"key":"B43","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0169-409X(01)00204-6","article-title":"Thermosensitive polymer-modified liposomes","volume":"53","author":"Kono","year":"2001","journal-title":"Adv. Drug Deliv. Rev"},{"key":"B44","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/jps.23773","article-title":"Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems","volume":"103","author":"Kraft","year":"2014","journal-title":"J. Pharm. Sci"},{"key":"B45","doi-asserted-by":"publisher","first-page":"328","DOI":"10.3109\/09687688.2010.522204","article-title":"Liposomes targeting tumour stromal cells","volume":"27","author":"Kuijpers","year":"2010","journal-title":"Mol. Membr. Biol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"10907","DOI":"10.1021\/cr500314d","article-title":"Noninvasive imaging of nanomedicines and nanotheranostics: principles, progress, and prospects","volume":"115","author":"Kunjachan","year":"2015","journal-title":"Chem. Rev"},{"key":"B47","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.ijpharm.2013.02.046","article-title":"Smart drug delivery systems: back to the future vs. clinical reality","volume":"454","author":"Lammers","year":"2013","journal-title":"Int. J. Pharm"},{"key":"B48","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jconrel.2011.09.063","article-title":"Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress","volume":"161","author":"Lammers","year":"2012","journal-title":"J. Control Release"},{"key":"B49","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.dld.2013.03.019","article-title":"Nanotechnology in diagnostics and therapeutics for gastrointestinal disorders","volume":"45","author":"Laroui","year":"2013","journal-title":"Dig. Liver Dis"},{"key":"B50","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ctrv.2017.03.004","article-title":"Local co-administration of gene-silencing RNA and drugs in cancer therapy: State-of-the art and therapeutic potential","volume":"55","author":"Larsson","year":"2017","journal-title":"Cancer Treat. Rev"},{"key":"B51","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.smim.2017.09.011","article-title":"Effects of engineered nanoparticles on the innate immune system","volume":"34","author":"Liu","year":"2017","journal-title":"Semin. Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.2217\/nnm.14.140","article-title":"Quo vadis nanomedicine?","volume":"9","author":"Luxenhofer","year":"2014","journal-title":"Nanomedicine"},{"key":"B53","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jconrel.2006.04.014","article-title":"Toxicity of cationic lipids and cationic polymers in gene delivery","volume":"114","author":"Lv","year":"2006","journal-title":"J. Control Release"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z","article-title":"Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma","volume":"89","author":"Lyass","year":"2000","journal-title":"Cancer"},{"key":"B55","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.addr.2015.01.002","article-title":"Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity","volume":"91","author":"Maeda","year":"2015","journal-title":"Adv. Drug Deliv. Rev"},{"key":"B56","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.addr.2012.10.002","article-title":"The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo","volume":"65","author":"Maeda","year":"2013","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"B57","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1194\/jlr.M800405-JLR200","article-title":"Gadolinium-containing phosphatidylserine liposomes for molecular imaging of atherosclerosis","volume":"50","author":"Maiseyeu","year":"2009","journal-title":"J. Lipid. Res"},{"key":"B58","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0169-409X(99)00043-5","article-title":"Immunoliposomes for the targeted delivery of antitumor drugs","volume":"40","author":"Mastrobattista","year":"1999","journal-title":"Adv. Drug. Deliv. Rev"},{"key":"B59","first-page":"6387","article-title":"A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs","author":"Matsumura","year":"1986","journal-title":"Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1136\/ard.2003.009944","article-title":"Liposomal targeting of glucocorticoids to synovial lining cells strongly increases therapeutic benefit in collagen type II arthritis","volume":"63","author":"Metselaar","year":"2004","journal-title":"Ann. Rheum. Dis"},{"key":"B61","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1002\/art.11140","article-title":"Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes","volume":"48","author":"Metselaar","year":"2003","journal-title":"Arthritis Rheum"},{"key":"B62","doi-asserted-by":"crossref","DOI":"10.1201\/9781315152356","volume-title":"Nanomedicine for Inflammatory Diseases.","author":"Milane","year":"2017"},{"key":"B63","doi-asserted-by":"publisher","first-page":"11147","DOI":"10.1021\/acs.chemrev.5b00116","article-title":"Clinical translation of nanomedicine","volume":"115","author":"Min","year":"2015","journal-title":"Chem. Rev"},{"key":"B64","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1007\/s13346-016-0352-5","article-title":"Nanoengineered strategies for siRNA delivery: from target assessment to cancer therapeutic efficacy","volume":"7","author":"Mishra","year":"2017","journal-title":"Drug. Deliv. Transl. Res"},{"key":"B65","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v18.i6.30","article-title":"Capture of stealth nanoparticles by the body's defences","volume":"18","author":"Moghimi","year":"2001","journal-title":"Crit. Rev. Ther. Drug Carrier Syst"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/j.addr.2012.06.006","article-title":"Nanotheranostics for personalized medicine","volume":"64","author":"Mura","year":"2012","journal-title":"Adv. Drug Deliv. Rev"},{"key":"B67","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.nano.2009.06.001","article-title":"Translational nanomedicine: status assessment and opportunities","volume":"5","author":"Murday","year":"2009","journal-title":"Nanomedicine"},{"key":"B68","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1517\/17425247.2014.955011","article-title":"Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls","volume":"12","author":"Nakamura","year":"2015","journal-title":"Expert Opin Drug Deliv"},{"key":"B69","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1002\/jps.23691","article-title":"Pharmaceutical development and regulatory considerations for nanoparticles and nanoparticulate drug delivery systems","volume":"102","author":"Narang","year":"2013","journal-title":"J. Pharm. Sci"},{"key":"B70","first-page":"1197","article-title":"A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model","volume":"60","author":"Needham","year":"2000","journal-title":"Cancer Res"},{"key":"B71","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.2147\/IJN.S47129","article-title":"Nanomedicine for drug targeting: strategies beyond the enhanced permeability and retention effect","volume":"9","author":"Nehoff","year":"2014","journal-title":"Int. J. Nanomedicine"},{"key":"B72","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1021\/ar300022h","article-title":"Nanomaterial toxicity testing in the 21st century: use of a predictive toxicological approach and high-throughput screening","volume":"46","author":"Nel","year":"2013","journal-title":"Acc. Chem. Res"},{"key":"B73","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.jconrel.2014.03.057","article-title":"EPR: evidence and fallacy","volume":"190","author":"Nichols","year":"2014","journal-title":"J. Control Release"},{"key":"B74","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jconrel.2012.01.027","article-title":"Safety assessment of nanomaterials: implications for nanomedicine","volume":"161","author":"Nystrom","year":"2012","journal-title":"J. Control Release"},{"key":"B75","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.addr.2017.07.007","article-title":"Pharmacological and physical vessel modulation strategies to improve EPR-mediated drug targeting to tumors","volume":"119","author":"Ojha","year":"2017","journal-title":"Adv. Drug Deliv. Rev"},{"key":"B76","doi-asserted-by":"publisher","first-page":"334","DOI":"10.3109\/17435390.2013.802387","article-title":"Concern-driven integrated approaches to nanomaterial testing and assessment\u2013report of the NanoSafety Cluster Working Group 10","volume":"8","author":"Oomen","year":"2014","journal-title":"Nanotoxicology"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1517\/17425247.2013.805742","article-title":"Strategies for triggered drug release from tumor targeted liposomes","volume":"10","author":"Oude Blenke","year":"2013","journal-title":"Expert. Opin. Drug Deliv"},{"key":"B78","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/j.1748-720X.2009.00441.x","article-title":"Developing, U.S. oversight strategies for nanobiotechnology: learning from past oversight experiences","volume":"37","author":"Paradise","year":"2009","journal-title":"J. Law Med. Ethics"},{"key":"B79","first-page":"1172","article-title":"Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery","volume":"8","author":"Park","year":"2002","journal-title":"Clin. Cancer Res"},{"key":"B80","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jconrel.2017.07.030","article-title":"The drug delivery field at the inflection point: Time to fight its way out of the egg","volume":"267","author":"Park","year":"2017","journal-title":"J. Control Release"},{"key":"B81","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0091-679X(08)60468-9","article-title":"Lipid vesicles as carriers for introducing biologically active materials into cells","volume":"14","author":"Poste","year":"1976","journal-title":"Methods Cell Biol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v26.i6.10","article-title":"Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic","volume":"26","author":"Puri","year":"2009","journal-title":"Crit. Rev. Ther. Drug Carrier Syst"},{"key":"B83","first-page":"567","article-title":"Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation","volume":"2","author":"Rahman","year":"2007","journal-title":"Int. J. Nanomedicine"},{"key":"B84","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1002\/anie.200802585","article-title":"Nanomedicine\u2013challenge and perspectives","volume":"48","author":"Riehemann","year":"2009","journal-title":"Angew. Chem. Int. Ed. Engl"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.copbio.2013.02.020","article-title":"Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications","volume":"24","author":"Rizzo","year":"2013","journal-title":"Curr. Opin. Biotechnol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.bbrc.2015.08.023","article-title":"Regulatory aspects on nanomedicines","volume":"468","author":"Sainz","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s11948-015-9705-6","article-title":"Defining Nano, Nanotechnology and Nanomedicine: Why Should It Matter?","volume":"22","author":"Satalkar","year":"2015","journal-title":"Sci. Eng. Ethics"},{"key":"B88","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1208\/s12248-012-9330-0","article-title":"Challenges in development of targeted liposomal therapeutics","volume":"14","author":"Sawant","year":"2012","journal-title":"AAPS J"},{"key":"B89","first-page":"123","article-title":"Fate and behavior of liposomes in vivo: a review of controlling factors","volume":"3","author":"Senior","year":"1987","journal-title":"Crit. Rev. Ther. Drug Carrier Syst"},{"key":"B90","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3389\/fphar.2015.00286","article-title":"Advances and challenges of liposome assisted drug delivery","volume":"6","author":"Sercombe","year":"2015","journal-title":"Front. Pharmacol"},{"key":"B91","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S0022-2275(20)43097-4","article-title":"Phospholipid spherules (liposomes) as a model for biological membranes","volume":"9","author":"Sessa","year":"1968","journal-title":"J. Lipid. Res"},{"key":"B92","doi-asserted-by":"publisher","first-page":"36","DOI":"10.2174\/1567201813666160816105408","article-title":"Overcoming the challenges of siRNA delivery: nanoparticle strategies","volume":"14","author":"Shajari","year":"2017","journal-title":"Curr. Drug. Deliv"},{"key":"B93","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nrc.2016.108","article-title":"Cancer nanomedicine: progress, challenges and opportunities","volume":"17","author":"Shi","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"B94","first-page":"345","article-title":"Tolerability of liposomes in vivo","volume-title":"Liposome Technology. 3","author":"Storm","year":"1993"},{"key":"B95","first-page":"111","article-title":"Doxorubicin entrapped in sterically stabilized liposomes: effects on bacterial blood clearance capacity of the mononuclear phagocyte system","volume":"4","author":"Storm","year":"1998","journal-title":"Clin. Cancer Res"},{"key":"B96","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.cossms.2012.10.001","article-title":"Clinical translation of nanomedicines","volume":"16","author":"Svenson","year":"2012","journal-title":"Curr. Opin. Solid. State Mater. Sci"},{"key":"B97","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.tox.2005.07.023","article-title":"Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity","volume":"216","author":"Szebeni","year":"2005","journal-title":"Toxicology"},{"key":"B98","first-page":"1","article-title":"Adverse immune effects of liposomes: complement activation, immunogenicity and immune suppression","volume-title":"Harnessing biomaterials for nanomedicine: preparation, toxicity and applications","author":"Szebeni","year":"2009"},{"key":"B99","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/08982100902792855","article-title":"Liposome triggering of innate immune responses: a perspective on benefits and adverse reactions","volume":"19","author":"Szebeni","year":"2009","journal-title":"J. Liposome Res"},{"key":"B100","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.bbrc.2015.06.177","article-title":"Complement activation as a bioequivalence issue relevant to the development of generic liposomes and other nanoparticulate drugs","volume":"468","author":"Szebeni","year":"2015","journal-title":"Biochem. Biophys. Res. Commun"},{"key":"B101","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1208\/s12248-015-9772-2","article-title":"Translational nano-medicines: targeted therapeutic delivery for cancer and inflammatory diseases","volume":"17","author":"Talekar","year":"2015","journal-title":"AAPS J"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.2174\/138161210791208992","article-title":"Nanotechnology and nanomedicine: going small means aiming big","volume":"16","author":"Teli","year":"2010","journal-title":"Curr. Pharm. Des"},{"key":"B103","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jconrel.2014.03.007","article-title":"Characterizing EPR-mediated passive drug targeting using contrast-enhanced functional ultrasound imaging","volume":"182","author":"Theek","year":"2014","journal-title":"J. Control Release"},{"key":"B104","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/nyas.12403","article-title":"Nanomedicines: addressing the scientific and regulatory gap","volume":"1313","author":"Tinkle","year":"2014","journal-title":"Ann. N. Y. Acad. Sci"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1016\/j.addr.2006.09.009","article-title":"Multifunctional nanocarriers","volume":"58","author":"Torchilin","year":"2006","journal-title":"Adv. Drug Deliv. Rev"},{"key":"B106","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.addr.2013.08.012","article-title":"Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status","volume":"65","author":"van der Meel","year":"2013","journal-title":"Adv. Drug Deliv. Rev"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/nbt1006-1211","article-title":"The emerging nanomedicine landscape","volume":"24","author":"Wagner","year":"2006","journal-title":"Nat. Biotechnol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0169-409X(97)00083-5","article-title":"Ligand-targeted liposomes","volume":"29","author":"Willis","year":"1998","journal-title":"Adv. Drug Deliv. Rev"},{"key":"B109","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/sj.clpt.6100400","article-title":"Nanoparticles in medicine: therapeutic applications and developments","volume":"83","author":"Zhang","year":"2008","journal-title":"Clin. Pharmacol. Ther"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2018.00790\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T14:45:34Z","timestamp":1661611534000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2018.00790\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,17]]},"references-count":109,"alternative-id":["10.3389\/fphar.2018.00790"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2018.00790","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,17]]},"article-number":"790"}}